Aarti Pharmalabs challenges stamp duty order of ₹59.5 Crore via Gujarat High Court
Aarti Pharmalabs Limited has filed a Writ Petition challenging a ₹59.5 Crore stamp duty and penalty order from the Superintendent of Stamps, Gujarat. The order pertains to a demerger scheme sanctioned in September 2022. The company is contesting the levy through the Gujarat High Court.
The litigation involves a substantial amount of ₹59.5 Crore, which could impact the company's financials if the challenge is unsuccessful. However, the impact is medium as it is a legal challenge and the outcome is uncertain.
The company is challenging a significant financial penalty and stamp duty, which indicates a negative development.
Aarti Pharmalabs Limited has filed a Writ Petition before the Hon'ble High Court of Gujarat at Ahmedabad. This action challenges an order dated August 29, 2026, issued by the Office of the Superintendent of Stamps, Gandhinagar, Gujarat.
The order levied a total stamp duty and penalties amounting to ₹59,50,00,000 (Rupees Fifty-Nine Crore Fifty Lakh only). This levy is in respect of the Scheme of Arrangement (Demerger) that was sanctioned by the Hon'ble NCLT, Ahmedabad Bench on September 21, 2022.
This disclosure is a continuation of the company's previous communication on September 02, 2026, regarding the receipt of the aforementioned order.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.